Introducing SPEAR epTau 217 and eMTBR-Tau: Dissecting Alzheimer’s pathologies from early Tau phosphorylation to Tau tangles
Wednesday, September 9 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
The development of reliable blood-based biomarkers is transforming Alzheimer's disease (AD) research, offering new opportunities to detect pathological changes earlier and monitor disease progression with greater precision.
In this SelectScience® webinar, held in partnership with Spear Bio, experts will introduce two novel blood-based biomarker assays designed to advance AD research: SPEAR epTau 217 and SPEAR eMTBR-Tau.
This webinar will present new data on SPEAR epTau 217, which detects a distinct subset of pTau 217 that may represent an early AD-associated Tau species. You will learn how the assay delivers highly consistent results across paired venous and Tasso capillary blood samples and how its performance compares with other Tau biomarkers, including total pTau 217, BD-Tau, and BD-pTau 217.
We will also introduce SPEAR eMTBR-Tau, a plasma biomarker associated with neurofibrillary tangle pathology in late-stage AD. Data will show how plasma eMTBR-Tau levels increase markedly with advancing disease and correlate with neuropathological severity and Tau-PET burden, supporting its potential as a blood-based marker of Tau tangle pathology.
Join us to explore how these assays could enable more accessible, precise, and stage-specific assessment of Alzheimer’s disease pathology.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Speakers
Who should attend?
Academic researchers, pharmaceutical and biotechnology teams, CROs, translational scientists, and clinical laboratory researchers interested in Alzheimer’s disease biomarkers, tau biology, biomarker validation, clinical research, and the research-use evaluation of eMTBR-Tau and pTau 217.
Featured products
Request Quote for All Products
SPEAR TrueDetect™ eMTBR-Tau Assay Kit
Spear BioThe SPEAR TrueDetect™ eMTBR-Tau Assay is the first commercially available singleplex immunoassay for the quantitative measurement of eMTBR-Tau in human plasma. eMTBR-Tau is an emerging Core 2 biomarker associated with neurofibrillary tau tangle pathology in Alzheimer’s disease.
SPEAR TrueDetect™ epTau 217 Assay Kit
Spear BioThe SPEAR TrueDetect™ epTau 217 Assay is an ultra-sensitive immunoassay that measures a distinct subset of phosphorylated Tau 217 (pTau 217) in human plasma. The assay selectively detects pTau 217 species with unphosphorylated serine 199 and demonstrates highly consistent measurement between paired venous and capillary blood samples.
What will this webinar cover?
- The biological rationale for targeting early phosphorylation at Tau 217 (epTau 217) and microtubule-binding region Tau (eMTBR-Tau) as complementary blood-based biomarkers of Alzheimer's disease.
- How SPEAR epTau 217 and SPEAR eMTBR-Tau provide complementary insights into different stages of AD pathology, from early Tau alterations to neurofibrillary tangle formation.
- Analytical and clinical performance data demonstrating the robustness of SPEAR epTau 217 across venous and capillary blood collection, and the association of SPEAR eMTBR-Tau with Tau-PET burden and neuropathological severity.
- Potential applications of these next-generation biomarkers in AD research, clinical studies, and decentralized sample collection workflows.